导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.85% | 1197/4773 |
| 近一周 | -1.07% | 1620/5465 |
| 近一月 | -2.43% | 1655/5421 |
| 近一季 | -4.81% | 1901/5231 |
| 近半年 | -2.57% | 2195/4920 |
| 近一年 | 8.75% | 1284/4394 |
| 近两年 | 60.22% | 1234/2954 |
| 近三年 | 32.26% | 1006/2253 |
| 成立以来 | 150.05% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.94% 1124/4961 |
14.56% 1796/5312 |
- - |
- - |
| 2025 | 23.39% 1875/4813 |
2.52% 1348/3635 |
1.14% 2448/4076 |
19.56% 2130/4524 |
-0.47% 2507/4813 |
| 2024 | 6.02% 1793/3463 |
-1.54% 1239/2808 |
-2.29% 1169/3014 |
11.44% 2518/3129 |
-1.11% 1591/3463 |
| 2023 | -5.01% 708/2656 |
5.95% 739/2280 |
-3.39% 787/2385 |
-2.94% 801/2515 |
-4.39% 998/2655 |
| 2022 | -15.30% 415/2207 |
-12.47% 619/1919 |
4.92% 960/2016 |
-8.92% 231/2113 |
1.27% 1316/2208 |
| 2021 | 22.85% 135/1822 |
0.11% 313/1255 |
10.65% 446/1330 |
6.57% 217/1466 |
4.07% 371/1822 |
| 2020 | 24.58% 632/1250 |
-4.39% 361/1028 |
15.91% 466/1067 |
8.13% 732/1164 |
3.96% 881/1184 |
| 2019 | 29.34% 505/1092 |
29.20% 282/754 |
-6.90% 530/804 |
1.49% 396/850 |
5.95% 664/918 |
| 2018 | -28.03% 433/834 |
- - |
- - |
- - |
-12.50% 450/691 |
| 2017 | 4.20% 422/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.30% 356/605 |
- - |
- - |
- - |
- - |
| 2015 | 33.24% 68/575 |
- - |
- - |
- - |
- - |
| 2014 | 41.10% 123/237 |
- - |
- - |
- - |
- - |
| 2013 | 13.32% 34/186 |
- - |
- - |
- - |
- - |
| 2012 | -1.35% 129/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 南方上证380ETF联接A VS. 长安沪深300非周期A(740101) |